MediSafe Project app boosts adherence rates
HAIFA, Israel — Self-reported medication adherence rates increased among Type 2 diabetes patients using a mobile app, the maker of the app said Monday.
MediSafe Project said it reviewed adherence rates among Type 2 diabetic users of its app, finding compliance rates at least 26% higher than the generate rate for long-term diabetes therapies, which the World Health Organization reports as 50%. A January 2013 study of the app, which the company launched in November 2012, found similar rates.
"Diabetes is a growing disease that has to be controlled throughout a person’s entire life," MediSafe Project CEO Omri Shor said. "With MediSafe Project, diabetic patients can better control their condition, improve health outcomes and help provide peace of mind. When dealing with a chronic disease, convenience and routine are imperative."
The app is described as the first cloud-synced mobile medication reminder. The analysis was based on data from patients using a variety of branded and generic drugs, with the highest rate, 82%, found among users of Merck’s Januvia (sitagliptin), followed by users of generic sitagliptin, at 80%.
Mylan launches generic version of Trilipix
PITTSBURGH — Mylan has launched a generic drug for treating cholesterol problems, the company said Monday.
Mylan announced the launch of generic fenofibric acid delayed-release capsules in the 45-mg and 135-mg strengths.
The drug is a generic version of Abbott’s Trilipix, designed for use in combination with statin drugs and diet to reduce triglycerides and increase high-density lipoprotein or "good" cholesterol.
Various versions of the drug had sales of about $553.6 million during the 12-month period that ended in March, according to IMS Health.
CHPA names new VP finance and administration, CFO
WASHINGTON — The Consumer Healthcare Products Association on Monday announced that Lisa Murphy Early will join the association as VP finance and administration and CFO.
“Lisa is a highly experienced association executive with extensive financial, managerial and strategic planning experience in the non-profit and for-profit sectors,” stated CHPA president and CEO Scott Melville.
Early will be director of CHPA’s finance management, human resources, information technology, meetings and administration functions. She will also serve as a member of the association’s senior management team.
A graduate of Michigan State University, Early is a certified public accountant who previously served as CFO and SVP, finance & administration for the Biotechnology Industry Organization. In that role, she oversaw all finance and administrative operations, which included finance, accounting, human resources, information technology and office facilities.
“Lisa played a key role in growing BIO from a small niche association to one of Washington D.C.’s most influential industry associations,” Melville noted. “That experience will be incredibly valuable as we look to strengthen and expand CHPA’s capabilities on behalf of its members.”
Earlier in her career, Early held a variety of accounting and financial positions at several biotechnology and communications companies including director of accounting for American Mobile Satellite Corporation, a publicly traded telecommunications firm, and controller for OncorMed, a publicly traded biotechnology company.
Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.